Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central anxious technique, conolidine modulates alternate molecular targets. A Science Advances review identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://billk985qsr6.frewwebs.com/profile